Fresh Equities
Raises
Research
About
Looking for more information?

Contact our responsive and friendly client services team any time.

BOTANIX PHARMACEUTICALS LTD

INVESTOR PRESENTATION - BOTANIX PHARMACEUTICALS LTD

ASX:BOT

BOTANIX PHARMACEUTICALS LTD

Health Care

Botanix Pharma aims to develop​ next-generation therapeutics for the treatment of serious skin diseases. The company's mission is to improve the lives of patients battling acne, psoriasis and atopic dermatitis, by providing new treatment options for conditions that currently are inadequately addressed or are treated with therapeutics that are burdened with side effects profiles. The company is developing the potential of a synthetic active pharmaceutical ingredient known as cannabidiol which is currently being studied for the treatment of epilepsy, pain, arthritis and schizophrenia amongst other indications. Botanix is preparing for the first human trials utilizing synthetic cannabidiol in a proprietary drug delivery system (Permetrex™) for direct skin delivery of the therapy.

Read more

Market Cap

94.35m

Price at Close

$0.097

4w avg. Volume

7.16m

4w avg. Turnover

$712.82k

Announcements
announcementt+2 movementdate
  • Letter to Shareholders - AGM

    Notice Of Meeting

  • -

    21 Oct 2020

-

21 Oct 2020
  • Notice of Annual General Meeting/Proxy Form

    Notice Of Meeting

  • -

    21 Oct 2020

-

21 Oct 2020
  • Appendix 4C - Quarterly

    Commitments test entity quarterly reports · Market sensitive

  • +10.00%

    12 Oct 2020

+10.00%

12 Oct 2020
  • Response to ASX Price Query

    ASX Query · Market sensitive

  • -9.00%

    29 Sep 2020

-9.00%

29 Sep 2020
  • New Antimicrobial Data and Conference Presentation

    Periodic Reports · Market sensitive

  • -1.79%

    07 Sep 2020

-1.79%

07 Sep 2020
  • Annual Report to Shareholders with Revised Top 20

    Periodic Reports

  • -1.79%

    07 Sep 2020

-1.79%

07 Sep 2020
  • Appendix 4G

    Periodic Reports

  • +2.08%

    31 Aug 2020

+2.08%

31 Aug 2020
  • Appendix 4E and Annual Report to Shareholders

    Periodic Reports · Market sensitive

  • +2.08%

    31 Aug 2020

+2.08%

31 Aug 2020
  • BTX 1801 Phase 2a Antimicrobial Study Underway

    Progress Report · Market sensitive

  • -5.45%

    11 Aug 2020

-5.45%

11 Aug 2020
  • Appendix 4C - Quarterly

    Commitments test entity quarterly reports · Market sensitive

  • +1.96%

    29 Jul 2020

+1.96%

29 Jul 2020
Market Data

Current Price

$0.097

52WK HIGH

$0.14

52WK LOW

$0.023

1YR RETURN

-22.40%

1YR RETURN VS. SECTOR

-45.85%

90 DAY RETURN

+76.36%

ASX RANK

816

/2,010

SECTOR RANK

16

/47

SHARES OUTSTANDING

972.70m
ASX:BOT

BOTANIX PHARMACEUTICALS LTD

Health Care

Botanix Pharma aims to develop​ next-generation therapeutics for the treatment of serious skin diseases. The company's mission is to improve the lives of patients battling acne, psoriasis and atopic dermatitis, by providing new treatment options for conditions that currently are inadequately addressed or are treated with therapeutics that are burdened with side effects profiles. The company is developing the potential of a synthetic active pharmaceutical ingredient known as cannabidiol which is currently being studied for the treatment of epilepsy, pain, arthritis and schizophrenia amongst other indications. Botanix is preparing for the first human trials utilizing synthetic cannabidiol in a proprietary drug delivery system (Permetrex™) for direct skin delivery of the therapy.

Read more

Market Cap

94.35m

Price at Close

$0.097

4w avg. Volume

7.16m

4w avg. Turnover

$712.82k

ASX:BOT is not raising right now

Want to invest?

Fresh Equities

Copyright © 2020 Fresh Equities. All rights reserved. ACN 619 657 028. CAR: 001267539 of AFSL: 471379.

Contact Us

(03) 9028 2888

clients@freshequities.com

Address

Level 7, 388 Bourke St
Melbourne VIC 3000
Australia

Copyright © 2020 Fresh Equities. All rights reserved. ACN 619 657 028. CAR: 001267539 of AFSL: 471379.